Safety and performance of the ultrathin sirolimus-eluting coronary stent in an all-comer patient population: the S-FLEX UK-II registry.

ABSTRACT:

Objective

We evaluated the clinical safety and performance of the ultrathin strut biodegradable polymer-coated Supraflex Cruz (Sahajanand Medical TechnologiesLtd., Surat, India) sirolimus-eluting stent (SES) in an all-comer patient population requiring coronary stent implantation.

Study design

The study was a prospective, observational, multicentre, single-arm registry.

Study settings

The study was conducted at 19 NHS Hospitals across the UK, from March 2020 to September 2021.

Study participants

A total of 1904 patients with symptomatic coronary artery disease (age ≥18 years) who underwent percutaneous coronary intervention with at least one Supraflex Cruz SES were enrolled.

Primary and secondary outcomes measure

The primary endpoint was target lesion fa

SUBMITTER: Karthikeyan VJ 

PROVIDER: S-EPMC11499841 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature